CPC G01N 33/5014 (2013.01) [C12N 5/0018 (2013.01); C12N 5/0619 (2013.01); C12N 5/0623 (2013.01); C12N 5/0696 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); G01N 33/5058 (2013.01); C12N 2310/11 (2013.01); C12N 2310/20 (2017.05); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/33 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/34 (2013.01); C12N 2500/38 (2013.01); C12N 2500/44 (2013.01); C12N 2501/01 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/119 (2013.01); C12N 2501/13 (2013.01); C12N 2501/41 (2013.01); C12N 2501/60 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2503/02 (2013.01); C12N 2506/45 (2013.01); C12N 2533/52 (2013.01)] | 11 Claims |
1. A pharmaceutically acceptable salt of an antisense oligonucleotide wherein the oligonucleotide is the oligonucleotide compound TTAcActtaattatactTCC (SEQ ID NO: 626), wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
|